MINI FUTURE LONG - UCB | Real-time Bid/Ask 12:04:03 03/06/2024 BST | ||
| 7.09 EUR / 7.1 EUR | -1.32% |
|
| 3 months | +44.96% | ||
| 6 months | +499.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
UCB
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 7.05 | -1.95% |
| 31/05/24 | 7.19 | +2.86% |
| 30/05/24 | 6.99 | -0.85% |
| 29/05/24 | 7.05 | -0.70% |
| 28/05/24 | 7.1 | -0.84% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 08:42 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | UCB |
| Issuer | Morgan Stanley |
| WKN | ME2KB2 |
| ISIN | DE000ME2KB21 |
| Date issued | 25/10/2023 |
| Strike | 56.82 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.25 € |
|---|---|
| Lowest since issue | 1.05 € |
| Spread | 0.01 € |
| Spread % | 0.14% |
Company Profile
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Sector
-
Consensus: UCB
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
128.6
EUR
Average target price
126.4
EUR
Spread / Average Target
-1.76%
- Stock Market
- Certificates
- Certificat
